U.S. Markets closed
  • S&P Futures

    3,592.75
    +16.75 (+0.47%)
     
  • Dow Futures

    29,715.00
    +169.00 (+0.57%)
     
  • Nasdaq Futures

    11,945.50
    +40.25 (+0.34%)
     
  • Russell 2000 Futures

    1,830.30
    +13.20 (+0.73%)
     
  • Crude Oil

    43.12
    +0.06 (+0.14%)
     
  • Gold

    1,824.70
    -13.10 (-0.71%)
     
  • Silver

    23.33
    -0.30 (-1.26%)
     
  • EUR/USD

    1.1846
    0.0000 (-0.0000%)
     
  • 10-Yr Bond

    0.8570
    +0.0280 (+3.38%)
     
  • Vix

    22.66
    -1.04 (-4.39%)
     
  • GBP/USD

    1.3328
    +0.0006 (+0.0440%)
     
  • USD/JPY

    104.5670
    +0.0790 (+0.0756%)
     
  • BTC-USD

    18,446.21
    +186.48 (+1.02%)
     
  • CMC Crypto 200

    369.25
    +7.83 (+2.17%)
     
  • FTSE 100

    6,333.84
    -17.61 (-0.28%)
     
  • Nikkei 225

    26,179.50
    +652.13 (+2.55%)
     

Syros to Present at Upcoming Investor Conferences in March

·1 min read

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced it will present at the following upcoming investor conferences:

  • Cowen and Company 40th Annual Health Care Conference in Boston, MA on Monday, March 2, 2020 at 4:50 p.m. ET.

  • Oppenheimer 30th Annual Healthcare Conference in New York, NY on Wednesday March 18, 2020 at 10:55 a.m. ET.

Live webcasts of the presentations will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcasts will be available for approximately 30 days following each presentation.

About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust pipeline, including SY-1425, a first-in-class oral selective RARα agonist in a Phase 2 trial in a genomically defined subset of acute myeloid leukemia patients, and SY-5609, a highly selective and potent oral CDK7 inhibitor in a Phase 1 trial in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200224005002/en/

Contacts

Media Contact:
Naomi Aoki
Syros Pharmaceuticals
617-283-4298
naoki@syros.com

Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com